Phase Ib/II Trial of Epcoritamab Plus Ibrutinib in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06536049

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:28:23.985263+00:00

Published At

2026-02-19T00:00:00+00:00

Record Updated At

2026-02-19

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Grade 3b Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-02-19"

protocolSection.identificationModule.nctId

"NCT06536049"

protocolSection.identificationModule.officialTitle

"Phase Ib/II Trial of Epcoritamab Plus Ibrutinib in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Recurrent Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Grade 3b Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
• Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
• Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
• Recurrent Primary Mediastinal Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Transformed Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Grade 3b Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
• Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
• Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
• Refractory Primary Mediastinal Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Transformed Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.